Gambling disorder Mental and Behavioural Disorders
Conditions
Interventions
Participants will be randomized to either the treatment being evaluated (ICBT) or an active control group (IMI).
A randomization sequence was made before enrollment of patients by a statistician not
Sponsors
Sahlgrenska University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible participants are all patients that are treated at the Unit for gambling addiction and screen health, Sahlgrenska University, Gothenburg, Sweden, and that meet the following inclusion criteria: 1. 18-75 years old 2. Any gender 3. Meet DSM-5 criteria for Gambling Disorder 4. Have access to the internet 5. Are able to read and write Swedish fluently
Exclusion criteria
Exclusion criteria: Participants will be excluded if they: 1. Have somatic or psychiatric conditions that contraindicate treatment or severely hinders treatment participation (e.g. ongoing psychotic, manic or hypomanic episode, or a developmental disorder causing severe disability) 2. Have an increased risk of suicide (based on assessment during the diagnostic interview) 3. Are currently in another ongoing psychological treatment with similar content as the one offered in this study 4. Have started medication for a psychiatric condition during the last three weeks 5. Plan to start another treatment (psychotherapy or medication) for their gambling disorder during the course of the 8-week treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 07/12/2022: Gambling-related behaviour measured using the NODS: The NORC Diagnostic Screen for Gambling Problems (NODS) (Wickwire et al., 2008). NODS will be adapted to a 14-day version. It will be administered at assessment, baseline, every 14 days of treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. Previous primary outcome measure: Gambling-related behaviour measured using the NODS: The NORC Diagnostic Screen for Gambling Problems (NODS) (Wickwire et al., 2008) and The Time Line Follow Back (TLFB), adapted to measure pathological gambling (G-TLFB) (Hodgins & Makarchuk 2003). NODS will be adapted to a 14-day version. It will be administered at assessment, baseline, every 14 days of treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. The GTLFB will be administered at baseline, every 7 days during treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measure as of 07/12/2022: 1. Gambling-related behaviour measured using the Time Line Follow Back (TLFB), adapted to measure pathological gambling (G-TLFB) (Hodgins & Makarchuk 2003) The GTLFB will be administered at baseline, every 7 days during treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 2. Gambling-related cognitions assessed using The Gamblers Belief Questionnaire (GBQ) (Steenbergh, Meyers, May & Whelan, 2002) at baseline, after 28 days, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 3. Depressive symptoms assessed using The Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) at baseline, every 7 days during treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 4. Anxiety symptoms assessed using The Generalized Anxiety Disorder 7-item scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006) at baseline, after 28 days, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 5. Quality of life assessed using The Brunnsviken Brief Quality of Life Scale (BBQ) (Lindner et al., 2016) at baseline, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. Previous secondary outcome measure: 1. Gambling-related cognitions assessed using The Gamblers Belief Questionnaire (GBQ) (Steenbergh, Meyers, May & Whelan, 2002) at baseline, after 28 days, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 2. Depressive symptoms assessed using The Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) at baseline, every 7 days during treatment, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 3. Anxiety symptoms assessed using The Generalized Anxiety Disorder 7-item scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006) at baseline, after 28 days, at treatment end and at follow-ups at 6, 12 and 24 months post-treatment. 4. Quality of l | — |
Countries
Sweden
Outcome results
None listed